Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...

Scientists at KAIST have developed a groundbreaking method to convert colon cancer cells into healthy ones using a ...

A groundbreaking FDA approval has introduced a new treatment option specifically designed for colorectal cancer patients with ...

The Colorectal Cancer Alliance noted a greater than 90% survival rate with early detection and treatment. The FDA approved a new colorectal cancer (CRC) blood test, Guardant Health’s “Shield ...

Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to ...

A startling rise in colorectal cancer among young people calls for urgent action in early detection, prevention, and tailored ...

KAIST researchers have developed new technology that can transform colon cancer cells into normal-like cells. Led by ...

Cancer treatment access differs significantly between traditional Medicare and Medicare Advantage  (MA), according to new research from the University of Colorado Cancer Center.

Young people are being diagnosed with colon cancer in record numbers - and now ... wanted to wait for patients to stop their primary treatments. The researchers said: 'Our study suggests ...

If you can relate, there’s a new option that might change ... which in turn could potentially reduce colon cancer deaths because patients can get earlier treatment. The Shield test is already ...

NEW YORK, December 20 ... and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.

Wednesday is officially the first day of 2025, and with the new year comes the introduction of several new laws in Vermont ...